Monday, November 9, 2026
Amaero holds Q3 2026 earnings call
Amaero discussed its third-quarter 2026 results during an earnings call. The headline gives no figures or details from the call.
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
Supernus Pharmaceuticals receives bullish analyst coverage initiation
An analyst started covering Supernus Pharmaceuticals with a positive view. The initiation was among several analyst coverage starts noted for Monday.
Baird starts Amaero coverage with Outperform rating and $9 price target
Baird began covering Amaero and gave the stock an Outperform rating. The firm set a price target of $9 per share.
Thursday, October 8, 2026
Amaero Sets IPO Size at 3,883,496 Common Shares, Cuts Stifel as Underwriter
Amaero disclosed the number of common shares it plans to sell in its initial public offering. The company also ended Stifel's role as an underwriter for the deal.
Frequently asked questions
What is the latest news on AMRO?
Nov 9, 2026: Amaero holds Q3 2026 earnings call (Benzinga) · Nov 9, 2026: Amaero Inc. filed a report on a major company event (Form 8-K) (SEC) · Nov 9, 2026: Supernus Pharmaceuticals receives bullish analyst coverage initiation (Benzinga)
What has AMRO filed with the SEC recently?
Nov 9, 2026: Amaero Inc. filed a report on a major company event (Form 8-K)
Get AMRO news as it happens
Every headline, SEC filing and analyst action for AMRO on your live chart, with important news marked and alerts when it matters.
Try SEPT Free